Cycle control with desogestrel-containing oral contraceptives--comparison of a monophasic and triphasic regimen.
To examine the effect of mono- and triphasic desogestrel-containing oral contraceptives on cycle control. Multicenter, international (U.S. and Canada). About 4,000 women, aged 18-35, healthy, neither pregnant nor lactating, were followed for almost 37,700 cycles of use of a monophasic 150 micrograms desogestrel/30 micrograms ethinyl estradiol OC or Sunday- or day-1 start regimens of a triphasic preparation containing 50/100/150 micrograms desogestrel/35/30/30 micrograms ethinyl estradiol administered on a 7/7/7 schedule. Standard diary methods were used to collect data on breakthrough bleeding, spotting, and absence of withdrawal bleeding. The two formulations demonstrated very low and, in fact, remarkably similar rates of breakthrough bleeding, spotting, and absence of withdrawal bleeding. A statistical analysis of these characteristics of the total study populations, per cycle, revealed no statistically significant differences between the formulations. Although the triphasic formulation contains the lowest estrogen dose of any triphasic available, 33% less progestin than the monophasic formulation, it maintains comparable cycle control.